Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPRE | P23469 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371772 | 0.81 | PTPN1 (0.49) | KCNK2ALDH1A1POLBPTPN1PTPRC | |
| SCHEMBL4935341 | 0.78 | GPR35 (0.53) | ALDH1A1PTPN1PTPRCPTPN2PTPRA | |
| SCHEMBL5264007 | 0.78 | CHEK1 (0.43) | IGF2BP2KCNK2KCNK10CHEK1GAA | |
| SCHEMBL6518415 | 0.77 | CHEK1 (0.49) | IGF2BP2KCNK2KCNK10CHEK1GAA | |
| SCHEMBL4365650 | 0.76 | PTPN1 (0.49) | KCNK2GAAALDH1A1PTPN1PTPRC | |
| SCHEMBL4931639 | 0.76 | SIRT2 (0.59) | PTPN1PTPRAPTPN6 | |
| SCHEMBL17627523 | 0.75 | IGF2BP2 (0.60) | IGF2BP2KCNK2KCNK10GAAALDH1A1 | |
| SCHEMBL27054662 | 0.74 | IGF2BP2 (0.63) | IGF2BP2KCNK2KCNK10GAAALDH1A1 | |
| SCHEMBL27051936 | 0.74 | IGF2BP2 (0.63) | IGF2BP2KCNK2KCNK10GAAALDH1A1 | |
| SCHEMBL30468358 | 0.74 | CHEK1 (0.47) | IGF2BP2CHEK1GAAMAPK8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | IGF2BP2 1924/4885KCNK2 2823/4885KCNK10 3607/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | IGF2BP2 1539/4885KCNK2 3821/4885KCNK10 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.